Drug Reprofiling in the Age of Necessity: A Strategic-Clinical Synthesis for Therapeutic Clinical Outcome

Drug reprofiling, also referred to as drug repurposing or repositioning, finds new therapeutic applications for drugs that are already on the market or have already failed. It provides quicker, less expensive, and less dangerous alternatives to traditional drug discovery. In in addition to addressing unmet medical needs in a variety of fields, such as infectious, neurodegenerative, oncologic, cardiovascular, metabolic, autoimmune, parasitic, and rare diseases, this strategy makes use of established safety and pharmacokinetic profiles to shorten development timelines and costs. Phenotypic and target-based approaches as well as computational methods like molecular docking are examples of strategies. Its effects during the COVID-19 pandemic and in chronic conditions where innovation is desperately needed are demonstrated by case studies. Drug reprofiling enhances drug lifecycles, speeds up personalised medicine, and supports global health initiatives by integrating into research pipelines and regulatory frameworks.